March 2013 Br J Cardiol 2013;20:32–7 doi:10.5837/bjc.2013.007
Andrew Whittaker, Lee Rowell, Olayiwola Olatawura, Petra Poliacikova, Jason Glover, Carl I Brookes, Andrew J Bishop
Abstract
Introduction
On inference from a range of randomised clinical trials, timely primary percutaneous coronary intervention (PPCI) has become the optimal strategy for the treatment of ST-segment elevation myocardial infarction (STEMI).1-8 Despite the logistic complexity and potential for delay compared with fibrinolytic treatment, the standard outcomes of safety and effectiveness of PPCI are superior to fibrinolysis unless the time delay is substantial.9-12 These data have led to the decision that, not only should PPCI be the treatment of choice for STEMI in England, it must be available 24 hours per day, seven days per week.13 This generates log
|
Full text
